Andrew Wei
0000-0002-7514-3298
Alfred Hospital
151 papers found
Refreshing results…
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Extranodal marginal zone b‐cell lymphoma of mucosa‐associated lymphoid tissue of the gallbladder
Boosting platelet production
Bortezomib: Putting mantle cell lymphoma on death row
Hp34p Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (Malt) Type of the Gallbladder
Illustrated Pathology of the Bone Marrow:
Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+ 2 T> C) affecting the Fas gene
Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone
The Bcl-2 Family: Cancer's achilles' heel?
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells
P51. Defining the apoptotic pathways underlying histone deacetylase inhibitor-mediated tumor therapy
The BH3 Mimetic, ABT-737, Is Effective Against Bcl-2 Overexpressing Lymphoid Tumors.
Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
Therapeutic Molecules and Methods for Generating and/or Selecting Same
Apoptosis in Hematological Malignancies
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
CD 138 Immunostaining of Bone Marrow Trephine Specimens Is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias.
Missing publications? Search for publications with a matching author name.